Cutler Group LP Alkermes Plc. Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$22.0 - $31.87 $4,400 - $6,374	200 New	200 $4,000
Q1 2022 Apr 14, 2022	BUY	$23.07 - $27.99 $184,560 - $223,920	8,000 New	8,000 $210,000
Q2 2021 Jul 19, 2021	SELL	$18.78 - $25.15 $159,630 - $213,775	-8,500 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$18.21 - $23.2 $100,337 - $127,832	5,510 Added 184.28%	8,500 $158,000
Q4 2020 Jan 21, 2021	BUY	$15.39 - $22.1 $16,775 - $24,089	1,090 Added 57.37%	2,990 $59,000
Q2 2020 Jul 22, 2020	BUY	$13.31 - $19.41 $25,289 - $36,879	1,900 New	1,900 $36,000
Q1 2020 May 07, 2020	SELL	$13.06 - $21.24 $41,792 - $67,968	-3,200 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$17.29 - $21.74 $55,328 - $69,568	3,200 New	3,200 $65,000
Q4 2018 Feb 05, 2019	SELL	$27.94 - $44.61 $37,998 - $60,669	-1,360 Closed	0 $0
Q3 2018 Nov 07, 2018	SELL	$38.6 - $46.12 $12,622 - $15,081	-327 Reduced 19.38%	1,360 $57,000
Q1 2018 May 11, 2018	BUY	$53.61 - $67.26 $90,440 - $113,467	1,687 New	1,687 $97,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.